Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- HEK-293 CD-44 Hermes antigen glycosamino-glycans CD-44v 44h 44v6 w44 Ig-G1 Gln-21 Epican GP90 Lymphocyte Homing/adhesion Receptor GP-90 ECMR-III ECMR3 PGP1 Phagocytic Glycoprotein 1 CSPG8 CSPG-8 HCELL LHR MC56 MC-56 MDU2 MDU3 MDU-2 3 MIC4 MIC-4
- Product Overview:
CD44 is a type I transmembrane glycoprotein and cell adhesion molecule belonging to the cartilage link protein family with roles in cell-cell and cell-matrix interactions, signal transduction, and cell migration.{55241,55242,55243} It is comprised of an N-terminal extracellular globular domain with a link domain that binds to the extracellular matrix component hyaluronan (HA) and other glycosaminoglycans, a membrane-proximal stem structure, a transmembrane domain, and a cytoplasmic domain that facilitates interactions with cytoskeleton-associated proteins.{55241,55244} The stem structure of CD44 can be modified via inclusion of variant exons between amino acid residues 222 and 223, resulting in several variant (CD44v) isoforms with the shortest and most prevalent isoform, known as the standard isoform (CD44s) or hematopoietic isoform (CD44H), having no exon insertions at this position.{55241,55245,55246} CD44 is expressed in a variety of cell types, including endothelial and epithelial cells, fibroblasts, and leukocytes.{55242} Binding of CD44 to HA is induced in T cells and monocytes upon antigen recognition and activation by inflammatory stimuli, respectively.{55247} The interaction between CD44 and HA mediates T cell rolling and recruitment of leukocytes to sites of inflammation. Several CD44 isoforms are expressed in tumor cells, including CD44v6, the overexpression of which is associated with tumor differentiation and lymph node metastasis in patients with non-small cell lung cancer (NSCLC).{55248,55249} Cayman’s CD44 N-terminal Domain (human, recombinant) protein is a disulfide-linked homodimer. The reduced monomer, comprised of CD44 (amino acids 21-220) fused to human IgG1 Fc at its C-terminus, consists of 441 amino acids, has a calculated molecular weight of 49.1 kDa, and a predicted N-terminus of Gln21 after signal peptide cleavage. The monomer migrates at approximately 76 kDa by SDS-PAGE under reducing conditions.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.